We are live on
!
Find out more
EFM
E Fund Management Portfolio holdings
AUM
$3.37B
This Fund
S&P 500
This Quarter
Est. Return
-7.89%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
-$29.7M
(-2.7%)
Cap. Flow
+$110M
Cap. Flow
% of AUM
10.28%
Top 10 Holdings %
Top 10 Hldgs %
55.73%
Holding
349
New
26
Increased
163
Reduced
134
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$35.5M |
| 2 |
Grab
GRAB
|
+$33.3M |
| 3 |
Qualcomm
QCOM
|
+$25.7M |
| 4 |
Advanced Micro Devices
AMD
|
+$21.8M |
| 5 |
Sea Limited
SE
|
+$18.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mercado Libre
MELI
|
+$26.6M |
| 2 |
Meta Platforms (Facebook)
META
|
+$16M |
| 3 |
DIDI
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
|
+$6.5M |
| 4 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$2.35M |
| 5 |
ProShares Ultra Gold
UGL
|
+$1.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 34.29% |
| 2 | Technology | 26.19% |
| 3 | Communication Services | 11.91% |
| 4 | Healthcare | 11.24% |
| 5 | Real Estate | 7.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KYNB
301
Kyntra Bio
KYNB
$28.5M
| $204K | 0.02% |
626
-72
| -10% | -$23.2K |
|
302
Xencor
XNCR
$1.44B
| $204K | 0.02% |
7,855
-62
| -0.8% | -$1.77K |
|
303
American Tower
AMT
$77.7B
| $202K | 0.02% |
942
+19
| +2% | +$4.88K |
|
304
Centene
CNC
$31.3B
| $201K | 0.02% |
2,578
+177
| +7% | +$15.8K |
|
305
Protagonist Therapeutics
PTGX
$8.75B
| $201K | 0.02% |
23,848
-12,185
| -34% | -$115K |
|
|
MYOV
306
DELISTED
Myovant Sciences Ltd.
MYOV
| $200K | 0.02% |
11,153
-938
| -8% | -$15K |
|
|
EQRX
307
DELISTED
EQRx, Inc. Common Stock
EQRX
| $199K | 0.02% |
40,228
+18,353
| +84% | +$92.5K |
|
|
AGEN
308
Agenus
AGEN
$249M
| $197K | 0.02% |
4,885
-864
| -15% | -$44.1K |
|
309
Anavex Life Sciences
AVXL
$222M
| $194K | 0.02% |
18,815
-429
| -2% | -$4.53K |
|
310
Gossamer Bio
GOSS
$66.5M
| $189K | 0.02% |
15,769
-650
| -4% | -$8.07K |
|
311
Arcturus Therapeutics
ARCT
$157M
| $188K | 0.02% |
12,713
-1,022
| -7% | -$17.1K |
|
312
Coherus Oncology
CHRS
$217M
| $178K | 0.02% |
18,473
-7,517
| -29% | -$76.1K |
|
313
Sana Biotechnology
SANA
$885M
| $177K | 0.02% |
29,495
-12,957
| -31% | -$93.5K |
|
314
Heron Therapeutics
HRTX
$86.3M
| $175K | 0.02% |
41,391
-45,190
| -52% | -$177K |
|
|
VXRT
315
DELISTED
Vaxart
VXRT
| $158K | 0.01% |
72,516
+10,902
| +18% | +$37.6K |
|
316
Hewlett Packard
HPE
$63.2B
| $156K | 0.01% |
13,052
-613
| -4% | -$8.33K |
|
317
Nkarta
NKTX
$162M
| $146K | 0.01% |
+11,085
| New | +$159K |
|
|
KZR
318
DELISTED
Kezar Life Sciences
KZR
| $145K | 0.01% |
+1,682
| New | +$163K |
|
319
Atara Biotherapeutics
ATRA
$71.2M
| $139K | 0.01% |
1,467
+442
| +43% | +$49.6K |
|
320
ImmunityBio
IBRX
$7.44B
| $138K | 0.01% |
+27,804
| New | +$127K |
|
|
SGMO
321
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $136K | 0.01% |
27,723
-3,869
| -12% | -$19.9K |
|
322
Viatris
VTRS
$20.1B
| $133K | 0.01% |
15,557
+4,374
| +39% | +$43.1K |
|
323
Recursion Pharmaceuticals
RXRX
$1.57B
| $126K | 0.01% |
+11,859
| New | +$120K |
|
324
Alector
ALEC
$164M
| $122K | 0.01% |
12,866
-3,506
| -21% | -$37.9K |
|
325
Norwegian Cruise Line
NCLH
$8.89B
| $120K | 0.01% |
10,598
| – | – |
|
Similar funds
VFCM
DFO
DIA
5NCM
TAM
CS
OAM
QCG
E Fund Management's Q3 2022 Portfolio in Review
As of Q3 2022, E Fund Management held 349 positions worth $1.07B, down 2.7% from $1.1B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
E Fund Management deployed $110M of net new capital in Q3 2022, opening 26 new positions and adding to 163 existing holdings. Its largest new stake was TSMC: 430,000 shares worth $29.5M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 34% of assets, down from 36% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Mercado Libre, an estimated $26.6M trimmed.
- E Fund Management's largest Q3 2022 buy was TSMC: 430,000 shares worth $29.5M.
- E Fund Management added most to Grab in Q3 2022, an estimated $33.3M increase.
- E Fund Management's biggest Q3 2022 reduction was Mercado Libre, cutting an estimated $26.6M.
- E Fund Management fully exited DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share in Q3 2022, selling an estimated $6.5M.
- E Fund Management's ten largest holdings make up 56% of its $1.07B portfolio in Q3 2022.
- E Fund Management opened 26 new positions and closed 15 in Q3 2022.
- E Fund Management's portfolio value fell 2.7% quarter-over-quarter to $1.07B.
Based on E Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.